Preclinical AD is reflected in altered cerebrospinal fluid (CSF) AD biomarkers: amyloid-β (Aβ42), total-tau (t-tau), and phosphorylated tau (p-tau). This evidence concerns the gene MAPT and Alzheimer disease.